Group testing can improve the cost-efficiency of prospective-retrospective biomarker studies

Table 2 Simulation results for evaluating a prognostic biomarker in the setting of the E1900 trial

Biomarker	Treatment	Measure of Association	Relative Efficiency				Relative Cost-Efficiency
			RS-2	RS-3	GT-2	GT-3	RS-2	RS-3	GT-2	GT-3
FLD3-ITD	HD	log-OR	0.61	0.38	0.87	0.76	1.22	1.13	1.75	2.29
		log-ratio	0.57	0.34	0.87	0.76	1.15	1.03	1.74	2.26
		difference	0.60	0.37	0.87	0.76	1.19	1.12	1.75	2.29
	SD	log-OR	0.50	0.33	0.82	0.65	1.01	0.98	1.65	1.94
		log-ratio	0.49	0.31	0.83	0.66	0.98	0.94	1.65	1.97
		difference	0.51	0.34	0.83	0.65	1.02	1.01	1.65	1.96
DNMT3A	HD	log-OR	0.64	0.41	0.89	0.80	1.27	1.23	1.79	2.40
		log-ratio	0.60	0.39	0.89	0.78	1.20	1.17	1.78	2.33
		difference	0.61	0.41	0.89	0.78	1.23	1.22	1.78	2.35
	SD	log-OR	0.50	0.33	0.85	0.71	1.00	1.00	1.70	2.13
		log-ratio	0.50	0.33	0.85	0.70	0.99	0.99	1.70	2.11
		difference	0.51	0.34	0.85	0.71	1.01	1.03	1.71	2.13

ISSN: 1471-2288